Inhibrx Biosciences (INBX) Return on Capital Employed (2024 - 2025)
Inhibrx Biosciences' (INBX) quarterly Return on Capital Employed came in at 105.34% in Q4 2025, up 10061.0% year-on-year from N/an in Q4 2024, and down 8.61% on a QoQ basis from 96.99% in Q3 2025.
Inhibrx Biosciences (INBX) Return on Capital Employed (2024 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 2 years of Return on Capital Employed data on file, last reported at 105.34% in Q4 2025.
- On a quarterly basis, Return on Capital Employed rose 10061.0% year-over-year to 105.34% in Q4 2025; TTM through Dec 2025 was 105.34%, a 10061.0% increase from a year earlier, with the FY2025 full-year figure at 104.01%, up 5879.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 105.34%, down from 96.99% in the prior quarter.
- Over the last five years, Return on Capital Employed for INBX reached as high as 88.63% in Q2 2025 and fell as low as 205.95% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | -105.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -105.34% |
| Sep 30, 2025 | -96.99% |
| Jun 30, 2025 | -88.63% |
| Mar 31, 2025 | -178.82% |
| Dec 31, 2024 | -205.95% |
| Sep 30, 2024 | -188.30% |